SEC Form 4 · accession 0001140361-17-037761
CytomX Therapeutics, Inc. · CTMX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
William Michael Kavanaugh
Officer — CSO, Head Res.&Non-Clin. Dev.
Period of report
Oct 4, 2017
Accepted (ET)
Oct 6, 2017 · 12:20 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001501989
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stok | Oct 4, 2017 | M | 48,368 | $4.4728 | A | 62,285 | D | |
| Common Stock | Oct 4, 2017 | S | 48,368 | $24.34 | D | 13,917 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $4.4728 | Oct 4, 2017 | M | 48,368 | D | — | May 6, 2025 | Common Stock | 48,368 | 48,368 | D |
Explanation of responses
- F1The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.
- F2The shares subject to the option are fully vested and exercisable.